Prostate cancer (PCa) is one of the preeminent causes of mortality in men worldwide. Theragnostic, a combination of therapy and diagnostic, using radionuclide pairs to diagnose and treat disease, has been shown to be a promising approach for combating PCa. In PCa patients, bone is one of the most common sites of metastases, and about 90% of patients develop bone metastases. This review focuses on (i) clinically translated theragnostic radionuclide pairs for the management of PCa, (ii) radionuclide therapy of bone metastases in PCa, and (iii) a special emphasis on emerging theragnostic radionuclide pair, Copper-64/Copper-67 (64Cu/67Cu) for managing the disease.
Chhabra, Anupriya and Thakur, Mathew L, "Theragnostic Radionuclide Pairs for Prostate Cancer Management" (2022). Department of Radiology Faculty Papers. Paper 136.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
This article is the author's final published version in Biomedicines, Volume 10, Issue 11, November 2022, Article number 2787.
The published version is available at https://doi.org/10.3390/biomedicines10112787.
Copyright © 2022 by the authors. Licensee MDPI, Basel, Switzerland.This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).